Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death from refractory end-stage heart failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial

NCT00483197

End-stage Heart Failure Cardiomyopathies

UNKNOWN PHASE3

VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial

NCT00490347

End-Stage Heart Failure Cardiomyopathies

COMPLETED PHASE2

Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

NCT00751972

Chronic Heart Failure

COMPLETED NA

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation

NCT00121472

Heart Failure, Congestive Ventricular Dysfunction Cardiomyopathies

COMPLETED NA

VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy

NCT00490321

End-stage Heart Failure Cardiomyopathies

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The HeartAssist 5® VAD System is intended for use as a bridge to heart transplantation and will be compared to the HeartMate II and HVAD devices.

Patients that meet the study criteria will be randomized 1:1 to either the HeartAssist 5® VAD System (treatment group) or control group (HeartMate II and HVAD). The physician will have the option to choose which control device to implant.

The primary objective of the study is to show non-inferiority of the HeartAssist 5® (treatment group) to the control group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Cardiac Failure Congestive Heart Failure Heart Failure, Left-sided

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HeartAssist 5® VAD System

Implant of the HeartAssist 5® VAD System

Group Type EXPERIMENTAL

HeartAssist 5® VAD System

Intervention Type DEVICE

The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.

Control VAD

Group Type ACTIVE_COMPARATOR

Control VAD

Intervention Type DEVICE

The HeartMate II® VAD or HVAD®

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HeartAssist 5® VAD System

The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.

Intervention Type DEVICE

Control VAD

The HeartMate II® VAD or HVAD®

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to sign Informed Consent.
2. Age ≥ 18
3. Body Surface Area (BSA) ≥ 1.2 m2.
4. Cardiac transplant candidate, defined as: Listed for cardiac transplant, and designated by the institution's multidisciplinary transplant committee as appropriate forLVAD Bridge-to-Transplantation therapy, or Designated by the institutions's multidisciplinary transplant committee as: 1) an appropriate candidate for LVAD Bridge-to transplant therapy, and 2) An inappropriate candidate for LVAD destination therapy
5. LVAD implantation has been approved by the institution's multidisciplinary transplant committee.
6. Patient is NYHA Class IV.
7. Able to return to the clinical site for all routine follow up visits.

Exclusion Criteria

1. Cardiothoracic surgery within 30 days prior to enrollment.
2. Acute Myocardial Infarction within 14 days prior to enrollment.
3. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty or left ventricular assist device.
4. Mechanical, animal, or human tissue heart valve.
5. History of untreated abdominal or thoracic aortic aneurysm \> 5 cm.
6. On ventilator support for \> 72 hours within four days immediately prior to enrollment.
7. Ongoing mechanical circulatory support other than an intra-aortic balloon pump (IABP).
8. Proven history of pulmonary embolism within 90 days of enrollment.
9. Moderate to severe aortic insufficiency as determined by echocardiogram without plans for correction during pump implantation surgery.
10. Requires aortic, mitral, tricuspid or pulmonary valve replacements (including Bioprosthetic valves) or left ventricular (LV) aneurysm resection.
11. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelets \<100,000, INR \> 1.6 or PTT \> 2.5 times control in the absence of anticoagulation therapy)
12. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support OR extracorporeal membrane oxygenation (ECMO) at the time of implantation OR right atrial pressure \> 20 mmHg while on multiple inotropes.
13. Significant renal dysfunction defined as \> 3.5 mg/dl or requires hemo or peritoneal dialysis for renal failure (excluding ultra-filtration for fluid removal).
14. Evidence of intrinsic hepatic disease defined as liver enzyme values (AST, ALT and LDH that are \> 3 times the upper limit of normal) OR a total bilirubin \> 3 mg/dl OR biopsy proven liver cirrhosis or portal hypertension.
15. Pregnancy
16. Active systemic infection prior to study enrollment not yet resolved by treatment. Active Systemic Infection is defined by any one of the following in spite of antibiotic, antiviral or antifungal treatment: 2 or more consecutive positive cultures; elevated temperature \> 37.2 (°C) and white blood cell count \> 11.0 (103/ml); hypotension, tachycardia and generalized malaise.
17. Stroke within 90 days prior to enrollment OR patient has a history of cerebral vascular disease with \> 80% extra cranial stenosis documented by carotid Doppler study during transplant evaluation
18. Modified Rankin Scale score of ≥ 2 or has any neurologic disability as confirmed by imaging (CT or MRI).
19. Significant lower extremity peripheral vascular disease accompanied by rest pain or leg ulceration.
20. Intolerant to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
21. Psychiatric disorder, or other psychosocial behavior that is likely to impair compliance with the study protocol.
22. Receiving therapy with an investigational intervention or participating in any other clinical investigation at the time of enrollment.
23. Condition, other than heart failure, that may limit survival to less than three (3) years and/or would exclude cardiac transplantation.
24. Unwilling or unable to comply with any study requirement.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No